XERS
Xeris Biopharma Holdings Inc

10,697
Mkt Cap
$998.86M
Volume
23.00
52W High
$10.08
52W Low
$3.59
PE Ratio
-58.22
XERS Fundamentals
Price
$5.94
Prev Close
$6.02
Open
$5.81
50D MA
$7.19
Beta
1.29
Avg. Volume
1.81M
EPS (Annual)
-$0.3736
P/B
-1,157.69
Rev/Employee
$515,406.09
$697.39
Loading...
Loading...
News
all
press releases
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results
Xeris Biopharma (NASDAQ:XERS - Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday...
MarketBeat·2d ago
News Placeholder
Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's What Happened
Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - What's Next...
MarketBeat·2d ago
News Placeholder
Xeris Biopharma Q4 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a defining milestone for the company: financial...
MarketBeat·2d ago
News Placeholder
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2d ago
News Placeholder
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of +84.62% and +5.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Xeris Biopharma Holdings Q4 Earnings Assessment
read more...
Benzinga·2d ago
News Placeholder
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...
Business Wire·2d ago
News Placeholder
Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3% - Should You Sell?
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 8.3% - Should You Sell...
MarketBeat·5d ago
News Placeholder
A Peek at Xeris Biopharma Holdings's Future Earnings
read more...
Benzinga·5d ago
<
1
2
...
>

Latest XERS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.